Nektar Therapeutics (NKTR) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $4.75B; Treasury Stock, ValueUSD (m).
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $4.38B; Treasury Stock, ValueUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $3.85B; Treasury Stock, ValueUSD (m).
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $3.81B; Treasury Stock, ValueUSD $0.00.
Nektar Therapeutics Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $3.00K | $4.75B | (m) | $-1.76M | $-3.85B | $903.12M | (m) | (m) | 3 month · $3.37M | (m) |
| 2026-03-31 | $0.00 | $3.00K | $4.38B | (m) | $-1.03M | $-3.81B | $576.22M | (m) | (m) | 3 month · $3.35M | (m) |
| 2025-12-31 | $0.00 | $2.00K | $3.85B | (m) | $17.00K | $-3.76B | $89.83M | 0.00 | (m) | 12 month · $12.65M | (m) |
| 2025-09-30 | $0.00 | $2.00K | $3.81B | $0.00 | $56.00K | $-3.72B | $85.09M | 0.00 | (m) | 3 month · $3.07M | (m) |
| 2025-06-30 | $0.00 | $1.00K | $3.67B | $3.00M | $-14.00K | $-3.69B | $-24.21M | 552.31K | (m) | 3 month · $3.49M | (m) |
| 2025-03-31 | $0.00 | $19.00K | $3.66B | $3.00M | $39.00K | $-3.65B | $13.74M | 8.29M | (m) | 3 month · $3.90M | (m) |
| 2024-12-31 | $0.00 | $1.00K | $3.66B | $3.00M | $61.00K | $-3.60B | $60.74M | 552.31K | 12 month · $3.00M | 12 month · $21.61M | (m) |
| 2024-09-30 | $0.00 | $19.00K | $3.65B | $3.00M | $355.00K | $-3.60B | $48.88M | 8.29M | (m) | 3 month · $5.39M | (m) |
| 2024-06-30 | $0.00 | $19.00K | $3.65B | $3.00M | $-494.00K | $-3.57B | $79.69M | 8.29M | (m) | 3 month · $5.42M | (m) |
| 2024-03-31 | $0.00 | $19.00K | $3.64B | $3.00M | $-403.00K | $-3.51B | $126.70M | 8.29M | 3 month · $3.00M | 3 month · $6.00M | (m) |
| 2023-12-31 | $0.00 | $19.00K | $3.61B | $0.00 | $80.00K | $-3.48B | $130.99M | 0.00 | (m) | 12 month · $33.39M | (m) |
| 2023-09-30 | $0.00 | $19.00K | $3.60B | (m) | $-6.35M | $-3.44B | $159.37M | (m) | (m) | 3 month · $8.15M | (m) |
| 2023-06-30 | $0.00 | $19.00K | $3.59B | (m) | $-6.45M | $-3.39B | $196.96M | (m) | (m) | 3 month · $7.97M | (m) |
| 2023-03-31 | $0.00 | $19.00K | $3.58B | (m) | $-5.68M | $-3.34B | $240.87M | (m) | (m) | 3 month · $10.02M | (m) |
| 2022-12-31 | $0.00 | $19.00K | $3.57B | (m) | $-6.91M | $-3.20B | $366.64M | (m) | (m) | 12 month · $57.32M | (m) |
| 2022-09-30 | $0.00 | $19.00K | $3.56B | (m) | $-8.17M | $-3.14B | $412.22M | (m) | (m) | 3 month · $12.52M | (m) |
| 2022-06-30 | $0.00 | $19.00K | $3.55B | (m) | $-8.19M | $-3.08B | $458.73M | (m) | (m) | 3 month · $11.10M | (m) |
| 2022-03-31 | $0.00 | $19.00K | $3.54B | (m) | $-6.53M | $-2.92B | $607.89M | (m) | (m) | 3 month · $20.96M | (m) |
| 2021-12-31 | $0.00 | $19.00K | $3.52B | (m) | $-4.16M | $-2.83B | $679.51M | (m) | (m) | 12 month · $94.67M | (m) |
| 2021-09-30 | $0.00 | $18.00K | $3.49B | (m) | $-3.56M | $-2.69B | $801.54M | (m) | (m) | 3 month · $24.66M | (m) |
| 2021-06-30 | $0.00 | $18.00K | $3.47B | (m) | $-3.40M | $-2.56B | $904.98M | (m) | (m) | 3 month · $23.71M | (m) |
| 2021-03-31 | $0.00 | $18.00K | $3.43B | (m) | $-3.12M | $-2.43B | $994.51M | (m) | (m) | 3 month · $23.90M | (m) |
| 2020-12-31 | $0.00 | $18.00K | $3.39B | (m) | $-2.29M | $-2.31B | $1.08B | (m) | (m) | 12 month · $94.26M | (m) |
| 2020-09-30 | $0.00 | $18.00K | $3.36B | (m) | $-1.08M | $-2.19B | $1.17B | (m) | (m) | 3 month · $23.67M | (m) |
| 2020-06-30 | $0.00 | $18.00K | $3.34B | (m) | $715.00K | $-2.08B | $1.26B | (m) | (m) | 3 month · $24.40M | (m) |
| 2020-03-31 | $0.00 | $17.00K | $3.31B | (m) | $-6.88M | $-2.00B | $1.30B | (m) | (m) | 3 month · $24.21M | (m) |
| 2019-12-31 | $0.00 | $17.00K | $3.27B | (m) | $-1.00M | $-1.86B | $1.41B | (m) | (m) | 12 month · $99.80M | (m) |
| 2019-09-30 | $0.00 | $17.00K | $3.24B | (m) | $-1.19M | $-1.75B | $1.49B | (m) | (m) | 3 month · $24.88M | (m) |
| 2019-06-30 | $0.00 | $17.00K | $3.21B | (m) | $-788.00K | $-1.65B | $1.56B | (m) | (m) | 3 month · $24.52M | (m) |
| 2019-03-31 | $0.00 | $17.00K | $3.18B | (m) | $-2.72M | $-1.54B | $1.63B | (m) | (m) | 3 month · $25.39M | (m) |
| 2018-12-31 | $0.00 | $17.00K | $3.15B | (m) | $-6.32M | $-1.42B | $1.72B | (m) | (m) | 12 month · $88.10M | (m) |
| 2018-09-30 | $0.00 | $17.00K | $3.12B | (m) | $-5.38M | $-1.33B | $1.79B | (m) | (m) | 3 month · $23.29M | (m) |
| 2018-06-30 | $0.00 | $17.00K | $3.09B | (m) | $-4.00M | $-1.23B | $1.86B | (m) | (m) | 3 month · $20.66M | (m) |
| 2018-03-31 | $0.00 | $16.00K | $2.26B | (m) | $-2.80M | $-2.20B | $58.28M | (m) | (m) | 3 month · $19.95M | (m) |
| 2017-12-31 | $0.00 | $15.00K | $2.21B | (m) | $-2.11M | $-2.12B | $87.83M | (m) | (m) | 12 month · $36.62M | (m) |
| 2017-09-30 | $0.00 | $15.00K | $2.17B | (m) | $-1.91M | $-2.08B | $84.16M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $0.00 | $15.00K | $2.15B | (m) | $-1.66M | $-2.14B | $3.39M | (m) | (m) | (m) | (m) |
| 2017-03-31 | $0.00 | $15.00K | $2.13B | (m) | $-1.85M | $-2.09B | $44.75M | (m) | (m) | (m) | (m) |
| 2016-12-31 | $0.00 | $15.00K | $2.11B | (m) | $-2.36M | $-2.02B | $88.12M | (m) | (m) | 12 month · $25.85M | 12 month · $439.00K |
| 2016-09-30 | $0.00 | $13.00K | $1.91B | (m) | $-1.96M | $-1.98B | $-67.85M | (m) | (m) | (m) | (m) |
| 2016-06-30 | $0.00 | $13.00K | $1.90B | (m) | $-2.02M | $-1.94B | $-39.25M | (m) | (m) | (m) | (m) |
| 2016-03-31 | $0.00 | $13.00K | $1.89B | (m) | $-1.83M | $-1.89B | $-275.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | $13.00K | $1.88B | (m) | $-2.17M | $-1.87B | $6.43M | (m) | (m) | 12 month · $19.67M | (m) |
| 2015-09-30 | $0.00 | $13.00K | $1.85B | (m) | $-1.82M | $-1.81B | $39.05M | (m) | (m) | (m) | (m) |
| 2015-06-30 | $0.00 | $13.00K | $1.84B | (m) | $-1.50M | $-1.81B | $35.10M | (m) | (m) | (m) | (m) |
| 2015-03-31 | $0.00 | $13.00K | $1.83B | (m) | $-1.28M | $-1.75B | $77.31M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $0.00 | $13.00K | $1.82B | (m) | $-1.57M | $-1.79B | $36.33M | (m) | (m) | 12 month · $17.02M | 12 month · $617.00K |
| 2014-09-30 | (m) | $12.00K | $1.79B | (m) | $-1.18M | $-1.74B | $47.22M | (m) | (m) | (m) | (m) |
| 2014-06-30 | $0.00 | $12.00K | $1.78B | (m) | $-887.00K | $-1.81B | $-35.36M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $12.00K | $1.77B | (m) | $-940.00K | $-1.78B | $-9.81M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | $11.00K | $1.64B | (m) | $-1.18M | $-1.73B | $-89.90M | (m) | (m) | 12 month · $17.71M | (m) |
| 2013-09-30 | (m) | $11.00K | $1.64B | (m) | $-1.69M | $-1.68B | $-50.25M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $11.00K | $1.63B | (m) | $-1.34M | $-1.67B | $-40.55M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $11.00K | $1.62B | (m) | $-395.00K | $-1.63B | $-2.62M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $11.00K | $1.62B | (m) | $-357.00K | $-1.57B | $47.02M | (m) | (m) | 12 month · $16.20M | (m) |
| 2012-09-30 | (m) | $11.00K | $1.61B | (m) | $155.00K | $-1.52B | $95.33M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $11.00K | $1.61B | (m) | $-620.00K | $-1.47B | $132.28M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $11.00K | $1.60B | (m) | $-43.00K | $-1.44B | $162.49M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $11.00K | $1.60B | (m) | $-1.10M | $-1.40B | $197.81M | (m) | (m) | 12 month · $18.89M | 12 month · $617.00K |
| 2011-09-30 | (m) | $11.00K | $1.59B | (m) | $-987.00K | $-1.36B | $230.80M | (m) | (m) | (m) | (m) |
| 2011-06-30 | $0.00 | $11.00K | $1.59B | (m) | $766.00K | $-1.34B | $251.28M | (m) | (m) | (m) | (m) |
| 2011-03-31 | $0.00 | $11.00K | $1.58B | (m) | $818.00K | $-1.30B | $281.24M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $0.00 | $9.00K | $1.35B | (m) | $968.00K | $-1.26B | $90.66M | (m) | (m) | 12 month · $17.40M | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $102.37M | (m) | (m) | 12 month · $10.33M | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $190.15M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |